General
Preferred name
CEFDINIR
Synonyms
CI-983 ()
FK-482 ()
PD 134393 ()
FK 482, PD 134393, CI-983 ()
Cefzon ()
NSC-758926 ()
BMY-28488 ()
FK 482 ()
Omnicef ()
Cefdinir anhydrous ()
Cefdinir ()
P&D ID
PD000564
CAS
91832-40-5
Tags
natural product
drug
available
Approved by
FDA
First approval
1997
Drug Status
approved
Drug indication
Bacterial infection
Antibacterial
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Cefdinir is a semisynthetic, third generation cephalosporin and belongs to the β-lactam class of antibacterial compounds . It has broad-spectrum activity against both Gram-positive and Gram-negative aerobic bacteria and is stable to hydrolysis by many common β-lactamases.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
20
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
38
Molecular Weight
395.04
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
4
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
1
cLogP
-0.17
TPSA
158.21
Fraction CSP3
0.21
Chiral centers
2.0
Largest ring
6.0
QED
0.23
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Microbiology&virology
Anti-infection
Target
PBPs
MPO
antibiotic
Bacterial
Antibiotics,Bacterial
Disease Area
infectious disease, otolaryngology, pulmonary
Indication
pneumonia, tonsillitis, pharyngitis, bronchitis, skin infections, otitis, sinusitis
MOA
bacterial cell wall synthesis inhibitor
Therapeutic Class
Antibiotics
Source data
